Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Manamley

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Advances in Therapy|November 1, 2013
Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM studyPeter Choi, Mourad Farouk, Nick Manamley, et al.
BMC Medical Research Methodology|July 14, 2016
Data sharing and the evolving role of statisticiansNick Manamley, Steve Mallett, Matthew R Sydes, et al.
Advances in Therapy|November 5, 2014
Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM studyJan Donck, Lourdes Gonzalez-Tabares, Jacques Chanliau, et al.
Pediatric Nephrology (Berlin, Germany)|October 21, 2015
Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry studyFranz Schaefer, Bernd Hoppe, Therese Jungraithmayr, et al.
Nephrology (Carlton, Vic.)|February 11, 2014
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysisSimon D Roger, Elena Kolmakova, Maple Fung, et al.
Blood Advances|March 1, 2024
Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphomaOwen A O'Connor, Bor-Sheng Ko, Ming-Chung Wang, et al.
Clinical Kidney Journal|May 30, 2013
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reductionEmanuel Zitt, Denis Fouque, Stefan H Jacobson, et al.
Mycoses|February 12, 2026
Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United KingdomNoemi Muszbek, Alisha Angdembe, Carolina Garcia-Vidal, et al.
Hematological Oncology|December 1, 2024
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I TrialAnna Sureda, Antonio Pinto, Hervé Ghesquières, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 19, 2016
Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort studyJan-Christoph Galle, Janet Addison, Michael G Suranyi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Advances in Therapy|November 1, 2013
Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM studyPeter Choi, Mourad Farouk, Nick Manamley, et al.
BMC Medical Research Methodology|July 14, 2016
Data sharing and the evolving role of statisticiansNick Manamley, Steve Mallett, Matthew R Sydes, et al.
Advances in Therapy|November 5, 2014
Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM studyJan Donck, Lourdes Gonzalez-Tabares, Jacques Chanliau, et al.
Pediatric Nephrology (Berlin, Germany)|October 21, 2015
Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry studyFranz Schaefer, Bernd Hoppe, Therese Jungraithmayr, et al.
Nephrology (Carlton, Vic.)|February 11, 2014
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysisSimon D Roger, Elena Kolmakova, Maple Fung, et al.
Blood Advances|March 1, 2024
Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphomaOwen A O'Connor, Bor-Sheng Ko, Ming-Chung Wang, et al.
Clinical Kidney Journal|May 30, 2013
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reductionEmanuel Zitt, Denis Fouque, Stefan H Jacobson, et al.
Mycoses|February 12, 2026
Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United KingdomNoemi Muszbek, Alisha Angdembe, Carolina Garcia-Vidal, et al.
Hematological Oncology|December 1, 2024
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I TrialAnna Sureda, Antonio Pinto, Hervé Ghesquières, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 19, 2016
Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort studyJan-Christoph Galle, Janet Addison, Michael G Suranyi, et al.
Pageof 2